A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CSL Limited
ClinicalTrials.gov Identifier:
NCT00940108
First received: July 13, 2009
Last updated: October 28, 2013
Last verified: October 2013
Results First Received: July 9, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Prevention
Condition: Influenza Caused by the Novel Influenza A (H1N1) Virus
Intervention: Biological: CSL425

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
One randomized participant withdrew consent prior to vaccine administration and was not included in the participant flow data or in any analysis population.

Reporting Groups
  Description
CSL425 (15 Mcg) Cohort A Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (30 Mcg) Cohort A Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (15 Mcg) Cohort B Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (30 Mcg) Cohort B Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.

Participant Flow:   Overall Study
    CSL425 (15 Mcg) Cohort A     CSL425 (30 Mcg) Cohort A     CSL425 (15 Mcg) Cohort B     CSL425 (30 Mcg) Cohort B  
STARTED     82     80     103     104  
COMPLETED     77     71     100     99  
NOT COMPLETED     5     9     3     5  
Adverse Event                 2                 4                 0                 2  
Withdrew Consent                 2                 1                 0                 1  
Dose 2 contraindicated                 1                 1                 0                 1  
Declined further vaccination                 0                 1                 3                 0  
Refused - pyrexia after Dose 1                 0                 1                 0                 0  
Viral illness after Dose 1                 0                 1                 0                 0  
Diagnosed with H1N1                 0                 0                 0                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
CSL425 (15 Mcg) Cohort A Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (30 Mcg) Cohort A Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (15 Mcg) Cohort B Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (30 Mcg) Cohort B Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
Total Total of all reporting groups

Baseline Measures
    CSL425 (15 Mcg) Cohort A     CSL425 (30 Mcg) Cohort A     CSL425 (15 Mcg) Cohort B     CSL425 (30 Mcg) Cohort B     Total  
Number of Participants  
[units: participants]
  82     80     103     104     369  
Age  
[units: years]
Mean ± Standard Deviation
  1.68  ± 0.67     1.73  ± 0.74     5.78  ± 1.69     5.66  ± 1.74     3.96  ± 2.42  
Gender  
[units: participants]
         
Female     41     41     53     49     184  
Male     41     39     50     55     185  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Haemagglutination Inhibition (HI) Antibody Titre Seroconversion Rate After the First Vaccination   [ Time Frame: Before and 21 days after the first vaccination ]

2.  Primary:   HI Antibody Titre Seroconversion Rate After the Second Vaccination   [ Time Frame: Before and 21 days after the second vaccination ]

3.  Primary:   Geometric Mean Fold Increase (GMFI) in the HI Antibody Titre After the First Vaccination   [ Time Frame: Before and 21 days after the first vaccination ]

4.  Primary:   GMFI in the HI Antibody Titre After the Second Vaccination   [ Time Frame: Before and 21 days after the second vaccination ]

5.  Primary:   Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More After the First Vaccination   [ Time Frame: 21 days after the first vaccination ]

6.  Primary:   Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More After the Second Vaccination   [ Time Frame: 21 days after the second vaccination ]

7.  Secondary:   Frequency and Intensity of Solicited Adverse Events (AEs) After the First or Second Vaccination   [ Time Frame: During the 7 days after each vaccination ]

8.  Secondary:   Duration of Solicited AEs After the First Vaccination   [ Time Frame: During the 7 days after the first vaccination and up to Day 20 after the first vaccination if AE is ongoing at Day 7. ]
  Hide Outcome Measure 8

Measure Type Secondary
Measure Title Duration of Solicited AEs After the First Vaccination
Measure Description Solicited AEs included AEs that were specifically sought for.
Time Frame During the 7 days after the first vaccination and up to Day 20 after the first vaccination if AE is ongoing at Day 7.  
Safety Issue Yes  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.

Reporting Groups
  Description
CSL425 (15 Mcg) Cohort A Participants aged 6 months to less than 3 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (30 Mcg) Cohort A Participants aged 6 months to less than 3 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (15 Mcg) Cohort B Participants aged 3 years to less than 9 years received two doses of CSL425 (15 mcg of haemagglutinin antigen per 0.25 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
CSL425 (30 Mcg) Cohort B Participants aged 3 years to less than 9 years received two doses of CSL425 (30 mcg of haemagglutinin antigen per 0.5 mL dose) by intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.

Measured Values
    CSL425 (15 Mcg) Cohort A     CSL425 (30 Mcg) Cohort A     CSL425 (15 Mcg) Cohort B     CSL425 (30 Mcg) Cohort B  
Number of Participants Analyzed  
[units: participants]
  82     80     103     104  
Duration of Solicited AEs After the First Vaccination  
[units: days]
Mean ± Standard Deviation
       
Pain at injection site     1.48  ± 0.677     1.52  ± 0.823     1.91  ± 1.221     1.80  ± 1.016  
Redness at injection site     2.08  ± 1.382     2.23  ± 1.602     2.26  ± 1.347     2.00  ± 1.134  
Swelling/induration at injection site     1.88  ± 0.957     1.64  ± 0.745     1.60  ± 0.737     2.04  ± 1.136  
Nausea/vomiting     1.33  ± 0.500     1.05  ± 0.213     1.18  ± 0.405     1.53  ± 1.837  
Diarrhoea     1.67  ± 1.328     1.55  ± 0.945     1.11  ± 0.333     1.17  ± 0.577  
Loss of appetite     2.32  ± 1.906     1.97  ± 1.447     NA  ± NA [1]   NA  ± NA [1]
Irritability     1.78  ± 1.560     1.73  ± 1.574     NA  ± NA [1]   NA  ± NA [1]
Fever     1.77  ± 1.547     1.52  ± 1.079     1.40  ± 0.737     1.54  ± 1.319  
Headache     NA  ± NA [2]   NA  ± NA [2]   2.04  ± 2.911     1.63  ± 1.149  
Muscle ache     NA  ± NA [2]   NA  ± NA [2]   1.45  ± 0.688     1.86  ± 2.175  
Malaise     NA  ± NA [2]   NA  ± NA [2]   1.60  ± 0.910     1.69  ± 1.966  
[1] Not solicited for in Cohort B
[2] Not solicited for in Cohort A

No statistical analysis provided for Duration of Solicited AEs After the First Vaccination



9.  Secondary:   Duration of Solicited AEs After the Second Vaccination   [ Time Frame: During the 7 days after the second vaccination and up to Day 20 after the second vaccination if AE was ongoing at Day 7. ]

10.  Secondary:   Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and New Onset of Chronic Illnesses (NOCIs)   [ Time Frame: Up to 180 days after the last vaccination ]

11.  Secondary:   Frequency and Intensity of Unsolicited Adverse Events After the First or Second Vaccination   [ Time Frame: During the 21 days after each vaccination; up to 180 days after the last vaccination for SAEs, AESIs, and NOCIs ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information